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ABSTRACT
Glycated haemoglobin (HbA1c) is now more commonly used as an alternative test to the fasting plasma glucose and oral glucose
tolerance tests for the identification of Type 2 Diabetes Mellitus (T2DM) because it is easily obtained using the point-of-care
technology and represents long-term blood sugar levels. According to WHO guidelines, HbA1c values of 6.5% or above are
required for a diagnosis of T2DM. However outcomes of a large number of trials with HbA1c have been inconsistent across the
clinical spectrum and further research is required to determine the efficacy of HbA1c testing in identification of T2DM. Medical
records from a diabetes screening program in Australia illustrate that many patients could be classified as diabetics if other
clinical indicators are included, even though the HbA1c result does not exceed 6.5%. This suggests that a cutoff for the general
population of 6.5% may be too simple and miss individuals at risk or with already overt, undiagnosed diabetes. In this study, data
mining algorithms have been applied to identify markers that can be used with HbA1c. The results indicate that T2DM is best
classified by HbA1c at 6.2% - a cutoff level lower than the currently recommended one, which can be even less, having assumed
the threshold flexibility, if additionally to HbA1c being high the rule is conditioned on oxidative stress or inflammation being
present, atherogenicity or adiposity being high, or hypertension being diagnosed, etc.
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1. INTRODUCTION
Diabetes Mellitus (DM), by far of the second type (T2DM),
is one of the world’s major chronic diseases anticipated to
rise to 439 million people by 2030.[1] This prevalence mo-
tivates the need for effective preclinical screening in order
to improve public health. Typically, T2DM is diagnosed
by blood plasma glucose criteria, either the fasting plasma
glucose (FPG) or the 2-h plasma glucose (2h-PG or TPG)
value after the 75-g oral glucose tolerance test (OGTT).[2]
In diagnosing DM clinicians follow guidelines setting limits
for TPG, FPG, or the glycated haemoglobin (HbA1c) levels.
The limits for TPG and FPG are known as impaired glucose
tolerance (IGT) and impaired fasting glucose (IFG), respec-
tively.[2] To be exact, IFG and IGT are value bands, either
one described as the prediabetic range, with the values below
described as normal and above as diabetic in the vicinity of
the range.
Evidence emerging from clinical trials demonstrates the ef-
fectiveness of targeted population screening in identifying
undiagnosed DM. In Europe, a randomized controlled trial
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associated a small, non-significant reduction in the incidence
of cardiovascular events and death with the early screening
and intensive multifactorial intervention for T2DM.[3] An
Australian study has evaluated an existing in the country
protocol for identification of undiagnosed T2DM and rec-
ommended the HbA1c assay as a cost effective measure to
reduce amount of FPG and TPG testing.[4]
HbA1c has several advantages to FPG and TPG if the ery-
throcyte function is normal.[5–7] HbA1c is a long-term indi-
cator for plasma glucose (PG) levels as it reflects average
glycaemia over the preceding 8-12 weeks[8] and is there-
fore considered a good surrogate marker for T2DM. Further,
HbA1c levels have been shown to be strongly correlated with
micro- and macro-vascular complications of T2DM, specif-
ically retinopathy[9] and cardio-vascular disease.[10] Also,
HbA1c overcomes some of the practical problems associ-
ated with obtaining FPG and TPG results: neither fasting is
required, nor needs the corresponding test be repeated as fre-
quently as the other two. In addition, HbA1c is more stable,
preserving better from the time of collection to the time of
assay, and has less specific storage requirements, compared
with glucose.
However, there is an incomplete correlation between HbA1c
and averaged PG levels, as well as between FPG and TPG.
These discrepancies is the biggest contributor to the statistics
of undiagnosed DM in the US where approximately 25% of
people have borderline results of the blood test for DM.[11]
According to ADA - the American Diabetes Association[2] it
is important to consider both demographic and clinical fea-
tures such as gender, age, race/ethnicity, sedentary lifestyle
and body mass index (BMI), anaemia/haemoglobinopathies,
as well as biomarkers known to be linked to DM in order
to determine risk levels of the disease. In addition, certain
medications such as atypical antipsychotics increase the risk
of DM and associated complications.[12] This may explain
that varied results are obtained world-wide for HbA1c as a
clinical marker in T2DM diagnostic.[8]
Beyond protein glycation, DM progression is linked to
markers of endothelial[13, 14] and autonomic nervous system
(ANS) dysfunction,[15, 16] inflammatory[17, 18] and oxidative
stress[19, 20] biomarkers. Recent literature reports that pres-
ence of 8-hydroxy-2’-deoxy-guanosine (8-OHdG) in blood
or urine samples is indicative of oxidative stress and deoxyri-
bonucleic acid (DNA) damage due to minor increases in
the PG level.[21, 22] In particular, the results of such studies
show a statistically significant increase of 8-OHdG levels
in prediabetic, and even a greater increase in diabetic par-
ticipants. Measures of total body fat also play a role in
assessing individual T2DM risk levels, though the exact re-
lationship between the weight and health outcomes is not
fully understood. A sustained body weight reduction is often
accompanied by improved glycaemic control in obese sub-
jects, with estimated 0.75% HbA1c absolute drop for every
10% loss in weight (and so BMI),[23] which competes with
what is achievable by medicinal means.[24] In this connec-
tion, even though some T2DM medicines are more effective,
weight loss promises a more permanent solution, while the
medicinal treatment may be for the price of weight gain.[24]
Hence, the T2DM risk prediction could be improved if the
estimates of body fat were included with existing risk scores.
In practice, BMI is used to assess weight, while waist cir-
cumference (WC) is regarded as a good indicator of the total
body fat. However, a single standard for these metrics cannot
be adopted as different classification criteria apply in differ-
ent population groups. So, the demographics like gender and
ethnicity should be included in risk prediction models.[1]
Threshold levels of HbA1c for the diagnosis of DM vary
across jurisdictions but 6.5% (48 mmol/mol) is adopted in
the US and Australia.[2, 7] However, it is plausible that, some
patients may have HbA1c below the threshold of 6.5% but
have levels of other markers that, when coupled with the near
miss values for HbA1c, are strongly indicative of T2DM. The
objective of the current study was to discover possible mark-
ers and respective thresholds that alongside HbA1c could
predict T2DM. The approach deployed was drawn from data
mining.
“Data mining” or “data analytics” refers to the process of dis-
covering interesting patterns from large amounts of data.[25]
The field has emerged in recent decades from statistics, ma-
chine learning and mathematics and involves algorithms for
data selection, cleaning, pre-processing, and ultimately for
analysing and learning from, typically very large datasets.
Clinical repositories that derive from electronic medical
records represent an exceptionally rich source of data for
mining that has been applied for the discovery of insights into
healthcare efficiencies, effective treatments, accurate prog-
noses and associations that stimulate medical research.[26]
In particular, data mining methods have been successfully
applied in systems providing logistic support for DM care
and treatment.[27]
To date, data mining techniques have not been systematically
applied for discovery of T2DM marker thresholds. How-
ever, data mining techniques are well suited for discovery of
ideal cut points for HbA1c under different clinical circum-
stances in conjunction with other factors that may impact
on the HbA1c value. The discovery of sophisticated rules
relating HBA1c and emerging biomarker levels, in particular,
presents as an interesting clinical model for data mining as
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T2DM has crisp cutoff values for diagnosis but a potentially
long preclinical period where complications of the disease
can already start to manifest. It is evident that the majority
of T2DM decision models so far were univariate, having
predominantly relied on PG[9, 10] or BMI[28, 29] measures as
sole risk factors. Very few models assume a multivariate risk
function[30] or are adaptive in nature.[31]
The application of data mining techniques for the discovery
of markers and threshold values in conjunction with HbA1c
requires following elements:
• An appropriate clinical dataset – a dataset that con-
tains data from the same patients on a large number of
biomarkers, demographics and other factors;
• A novel data analytical approach – the dataset requires
pre-processing to deal with outliers and missing values
in addition to mining algorithms that identify combina-
tions of markers and cutoff levels that predict T2DM;
• A format for depicting the combinations of markers
and thresholds that is simple enough to be rapidly in-
terpreted by clinicians and researchers.
2. MATERIALS AND METHODS
2.1 Clinical dataset
The dataset used in this study was derived from the Dia-
betes Screening Complications Research Initiative (DiScRi)
conducted at a regional Australian university.[32] The pro-
gram implemented all necessary measures to safeguard the
research ethics. Particularly, all participants provided in-
formed, written consent. The DiScRi community screening
concentrates on DM, Cardiovascular Disease (CVD) and
Hypertension (HT) as a triad of diseases, which are specif-
ically identified in the dataset. The screening clinic has
been collecting data for longer than ten years now, tracking
information such as demographics, socio-economic situa-
tion, and clinical test results. The clinical variables include
PG, HbA1c; the cholesterol profile: low density lipopro-
tein (LDL), high density lipoprotein (HDL), total cholesterol
(TC) and triglyceride (TG) concentrations in blood; inflam-
matory and oxidative stress markers from blood and urine;
peripheral vascular function parameters; electrocardiogram
(ECG) derived variables; blood pressure (BP) measurements,
both systolic (SBP) and diastolic (DBP); anthropometrics,
including BMI; as well as the medical history. Data on 300
attributes from 2,700 attendances of 900 patients have been
collected in recent years. The dataset has been used in sev-
eral data mining applications for identification of DM[33, 34]
and related conditions.[35, 36] The temporal data underwent
compression to instantiate patients instead of attendances by
calculating longitudinal means or modes on the amount of
available data. Type 1 DM (T1DM) patients were excluded
as this study is focused on T2DM.
The final dataset assembled for this study consisted of 99
attributes, of which 93% were incomplete, and 847 patient
records, less than 1% complete, with 45% of values missing
across all data. In addition, a number of features were gener-
ated upon completion using the existing set. The class struc-
ture for the main classification problem is taken as T2DM
being the diagnostic class (Class 1) and contributing 26% of
the data, with the rest assigned to the control class (Class
0). Having cases expert-labelled not only for T2DM but
also for CVD and HT - the linked conditions - is crucial for
subsequent data completion as approached in this work.
2.2 Novel data analytics
Missing values (MV) are often guessed/imputed for conve-
nience of dealing with complete data when applying classi-
fication or other data mining methods, which is a topic we
previously discussed in detail.[33] On a different occasion[34]
we followed an approach on a par with the General Location
Model[37] to set MV in then existing a version of the DiScRi
data, which is appropriate for mixed attribute type domains
consisting of continuous as well as of categorical features.
Values of categorical attributes naturally subdivide data into
clusters, allowing to use a small number of well-established
features of this type to set MV for all other attributes by
using mean or mode for each combination of values of the
selector attributes. If a continuous attribute, such as BMI,
has to be nominated a selector for influence it exerts on deci-
sion making, its range can be subdivided into a number of
intervals, adhering to some known thresholds. We recycle
these ideas here and propose a method which is a hybridi-
sation of the Hot Deck approach we previously evaluated
and advanced.[33] A difficulty is though presented by some
unknown outcomes that cannot be easily predicted, which is
expected of classification, because of MV in attributes the
decision is supposed to be based on. The Hot Deck approach,
which draws similar instances to enter MV by example, al-
lows to overcome this difficulty as the class attribute or any
other are treated the same. The class values can be set by a
single strongest predictor, subject to its value known, as we
did once.[34] More attributes, even though less strong, can be
deployed to enhance decision by ensuring greater similarity
between compared instances, which is indeed how the Hot
Deck method works. Although previously[33] we proposed
how to make use of this approach for all-categorical data
domains, it is most suited for all-continuous data domains.
The method advanced in this work is data type insensitive.
Features we use to guide the selection of data subsets to enter
MV by subset mean or mode are all well-established in the
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sense that they are long-known to be risk factors or indicators
of T2DM and conditions linked to it and, incidentally, are
well-supplied with values. As previously noted, the DiScRi
data provides classification not only in respect of T2DM but
also CVD and HT conditions. This is a favourable circum-
stance because it makes possible to ‘triangulate’ the location
that means or modes could be extracted from. Normally, we
would have to enjoy a single class attribute. So, the selec-
tor set includes: the T2DM, CVD and HT statuses, fasting
glucose, age, waist-circumference-to-height ratio (WCHR),
SBP lying, diabetic phenotype, joint cardio-vascular and joint
cardio-neuropathic facts, graded heart function on results of
ECG, combined causes of high BP, and gender. Indeed, the
Australian T2DM screening protocol identifies following risk
factors:[4]
• People aged 55+ years;
• People aged 45+ years who have one or more of the
following risk factors:
– Obesity (BMI 30+ kg/m2),
– First-degree relative with T2DM,
– Hypertension (SBP 140+ or DBP 90+ mmHg, or
taking antihypertensive medications);
• Aboriginal and Torres Strait Islanders aged 35+ years;
• People from high-risk non-English-speaking back-
ground groups aged 35+ years;
• People with IGT or IFG;
• People with clinical cardiovascular disease (myocar-
dial infarction, angina, or stroke);
• Women with previous gestational diabetes;
• Women with polycystic ovary syndrome who are
obese.
Thus, the selector set has a fair coverage of this list of long-
known risk factors and therefore one should expect that at
least this segment of data is available, which is indeed ob-
served. The ethnicity aspect is not captured by the selectors
as it is not readily accessible in the DiScRi data collection.
Although, the rural population is probably less multicultural
than urban in Australia. The gender specific conditions are
either rare, or less consequential provided the T2DM sta-
tus is known, and are not reflected in the database. While
any additional selector information enhances specificity of
the data entry, some omissions are not essential for the data
completion in view of the assumed advance knowledge of
all T2DM, CVD and HT statuses, adding the specificity at
the highest level. This is beyond the domain knowledge and
is a part of the formulation itself. Otherwise, the choice
of selectors is unconventional in that BMI is replaced with
WCHR which we find to be more reliable, and this reflects
the contemporary leaning.[28, 29]
The order of selectors stipulates the sequence of MV entry.
Firstly, MV including the missing statuses are set in CVD and
HT problems, while all T2DM statuses are known. Having
obtained the statuses makes MV entry in all other attributes
more to the point. The problem which is staged with this
purpose is the combined T2DM, CVD and HT classifica-
tion problem where it is required to predict a combination
of the statuses. However, the inversion of this classification
problem is actually being solved. The order of selectors is
specific to a problem and is different for the CVD, HT and
the combined problem of T2DM, CVD and HT. The initial
order of selectors can be guessed using the domain knowl-
edge and refined after data completion using the Information
Gain (IG) criterion - the higher, the prior - but it is possible to
evaluate individual feature IG even from incomplete data.[33]
The strength of the scheme for the automated data entry de-
rives from the circumstance that the selectors, apart from
being well-known, also possess high IG. Particularly, all the
mentioned features but gender are on the joint top 20% list
where a feature is included if it has a sufficiently high IG at
least in one of the mentioned problems, that is, individual
T2DM, CVD and HT problems and the combined one. Of
course, the statuses are at the very top of IG lists in prob-
lems where they are set to be predicted. The advancement of
the proposed technique is that the moment a selector has is
dropped, due to its value set having been exhausted, and a
broader selection is attempted is delayed as much as possible.
Selectors with higher IG persist during the data entry, that is,
their values stay fixed longer. This, in particular, allows for
attracting data more suited for substituting MV from, earlier
in the process, and increases confidence of the data entry by
drawing on more reliable values previously entered. Once a
selector is switched off, it is treated as an ordinary variable,
and any MV in it are substituted then; however, the selector
comes into play once more when a higher standing selector
is exhausted. All selectors are eventually turned off when all
their value combinations are encompassed. Any MV that are
left out are then substituted from all data.
The whole analytics exercise is summed up in Figure 1.
The goal is to produce augmented HbA1c rules for T2DM
diagnostic. After taking advantage of the dynamic clus-
tering approach to substitute MV, the next challenge is to
induce decision trees to get the general idea of would-be
rules. Selected trees are then converted to models which are
subsequently optimised for performance.
The decision trees[38] are produced in the manner of the
Decision Branch algorithm previously introduced by us,[33]
although this time we are interested in whole trees, not in-
dividual branches. Accordingly, any continuous attributes
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are undergone discretisation, which was also covered. The
discretisation is only a temporary device to get the idea of
a particular tree structure. Various trees are produced by
staged-out transformation of the feature-set from where fea-
tures just next to the root in the current structure are withheld
one-by-one. HbA1c is invariably at the root. To guarantee
this all other PG related attributes are withheld from the out-
set. The resulting trees are then analysed with a view of their
structure simplification. Some little promising branches are
pruned out; similar branches at a same node are aggregated
into a single one by merging adjacent intervals on involved
continuous variables. The outcome of this process is creation
of a model out of each tree initially produced. The models
are essentially data prototypes in the decision tree form, free
from the stigma of discretisation. The models are then en-
tered into an optimisation routine and their parameters are
tuned for performance. Specifics of the involved calculations
are covered where appropriate in the text.
Figure 1. Stages of the analytical exercise
2.3 Representation format
Figure 2 schematises the decision taking based on a single
predictor variable and a single threshold. The variable in
the focus is HbA1c, and the standard threshold, or cutoff to
diagnose T2DM is 6.5%, although a different value may be
more to the point, which we’d like to find out. Orientation of
the threshold, more generally, a decision boundary that in the
scheme divides the continuous range of the variable into two
parts is also important. The standard rule reads “IF HBA1c >
6.5% THEN T2DM”. In the scheme the field with the ball
in it symbolises a ‘Yes’ decision, and the field without a ball
- a ‘No’ decision. If the decision is ‘Yes’, then the patient
being examined has T2DM. The horizontal arrow next to the
variable name, in this case HbA1c, is pointed in direction of
the value increase.
Figure 2. HBA1c-only decision rule by value over a
threshold
A decision rule based on a single variable and a single cut-
off may be too ‘sharp’. Even though the standing US and
Australian recommendations[7] formally include 6.5% with
the ‘Yes’ branch of the standard HbA1c rule, this exact value
or a close one is too ambiguous - a small error can cause a
dramatic decision change. Also, the precision of any mea-
surement is always limited. The HbA1c result is usually
known to one decimal place, so the gap between 6.4% and
6.6% is formally unaccounted for, if the threshold value of
6.5% is excised. To emphasise this, we always exclude the
decision boundary itself from either of the adjacent decision
regions. With this in mind, it seems to be more appropriate
allowing for an uncertainty gap in the decision rule and then
trying to elaborate the decision in the gap.
Figure 3 illustrates a concept decision tree that has been de-
signed to represent more complex rules in a manner that is
potentially clinically practical. The idea is to use a second
variable with a single threshold in the uncertainty range of
the first variable, here HbA1c. For the correction to work, the
second variable should be good enough to cover for shortfalls
of the first variable in the gap. However, this may be not that
restricting because, to be more informative as a set, variables
have to be if not independent from each other then different
enough. So, assuming all variables have their strong sides
when it comes to a decision in certain circumstances, use of a
different secondary variable will simply readjust position of
the indecision interval on the primary variable. The HbA1c
decision uncertainty interval in Figure 3 is distinguished by
the vertical arrow to express the necessity to expand into
another dimension, meaning that this range of values on the
primary variable should be additionally analysed using the
secondary one. Otherwise, the same schematics as in Figure
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2 applies. The orientation of the decision boundary for the
second variable, as depicted, is ‘over’ and is the same as for
HbA1c. We discuss another variant of orientation later in the
text.
Figure 3. HBA1c decision enhancement with second
variable over a threshold
The HbA1c cutoff is thus context sensitive and flexible,
as proposed, meaning that different thresholds apply when
HbA1c is taken in combination with another variable than if
it was taken on its own and that, instead of a single value in
the usual sense, such a threshold is represented by a band of
values. We sometimes use the terms ‘threshold’ and ‘cutoff’
in that sense. Data mining algorithms are able to identify
factors that can be used jointly with HbA1c and generate
unique thresholds for a tailored diagnostic of T2DM. The
results of actual mining of the DiScRi data are described in
the next section.
3. RESULTS
Table 1 parameterises selected decision trees obtained by
extension of the standard HbA1c rule as illustrated in Fig-
ure 3, listing them in the order of diminishing predictive
accuracy. We use a decision tree classifier, as explained, to
arrive at the idea of the trees. The trees are then optimised
to yield a highest predictive “Yes/No” accuracy of T2DM
on the DiScRi data. The actual quantity being maximised
is balanced accuracy, that is, simple mean of Classes 1 and
0 individual accuracies, or sensitivity and specificity,[25] re-
spectively. A rule is run through all of the data and the
statistics of successes are accumulated and combined at the
end. This is repeated many times for different values of the
rule parameters, until an optimal setting shown in the table
is found.
If decision changes from ‘No’ to ‘Yes’ in the direction of
increase of the auxiliary variable, which is how it appears
in Figure 3, the corresponding rule orientation in Table 1 is
stated as ‘over’, that is, if a particular reading of the auxiliary
variable is over the threshold as in the table, then the deci-
sion is ‘Yes’, providing the corresponding value of HbA1c
is within the interval of indecision in the table. Decision
is, otherwise, ‘No’ for lower values of HbA1c outside the
interval, or if within the interval, for lower values of the
extension variable. Decision is ‘Yes’ for higher values of
HbA1c outside the interval of indecision. If orientation in
the table is stated as ‘under’, this means that decision, based
on the corresponding auxiliary variable, changes from ‘No’
to ‘Yes’ in the direction opposite to direction of the variable
increase, as shown in Figure 4. Compared with Figure 3
the ball symbolising the ‘Yes’ decision is now found in the
opposite field.
Table 1. Enhanced HbA1c rules for T2DM diagnostic using
continuous extension variables
 
 
HbA1c indecision 
interval 
Auxiliary variable Balanced 
Accuracy 
(%) From(%) To(%) Name Orientation Threshold Unit 
4.92 6.23 8-OHdG over 982 pg/ml 86.64 
5.73 6.22 IL-6 over 64.0 pg/ml 85.63 
6.05 6.60 
IHR 
Sample 
Entropy 
under 1.54 
nonlinear 
pro-rata 
85.01 
5.70 6.22 TC under 4.03 mmol/L 84.38 
6.13 6.58 Protein over 70.0 g/L 84.37 
5.80 6.54 LDL under 2.74 mmol/L 84.30 
5.65 6.22 AIP over 0.159 
nonlinear 
pro-rata 
84.07 
6.10 6.58 
IHR 
Approx. 
Entropy 
under 1.27 
nonlinear 
pro-rata 
83.82 
6.10 6.51 
GSH / 
GSSG 
under 7.36 pro-rata 83.56 
5.80 6.22 Creatinine over 87.7 μmol/L 83.28 
6.10 6.56 BMI over 24.4 kg/m2 83.04 
6.06 6.80 TG over 0.747 mmol/L 83.03 
6.00 6.61 WCHR over 0.562 pro-rata 82.97 
6.10 6.19 
QRS (over 
10 s) 
under 114 ms 82.73 
6.20 6.81 CRP over 0 mg/L 82.46 
- - HbA1c over 6.20 per-cent 82.46 
 
Figure 4. HBA1c decision enhancement with second
variable under a threshold
Should an additional condition, expressed verbally but other
than the one involving a continuous variable, be met this
nonetheless can be modelled using a binary auxiliary vari-
able where ‘0’ corresponds to the state when the condition is
not met, and ‘1’ when it is. We could denote ‘0’ and ‘1’ as
116 ISSN 1927-6974 E-ISSN 1927-6982
http://air.sciedupress.com Artificial Intelligence Research 2016, Vol. 5, No. 1
‘no’ and ‘yes’, respectively. The outcome of decision making
is that kind of variable. Alternatively, we could make use
of a continuous auxiliary variable with the threshold of zero
where ‘<0’ is equivalent to ‘no’ and ‘>0’ to ‘yes’. Then it
is possible to apply the schematics in Figure 3 where the
orientation is ‘over’. If it was ‘under’, that would mean that
if the additional condition is met the decision is ‘No’, which
is how it appears in Figure 4; however, such an occurrence
is unconventional in diagnostics. The representation using
a binary variable is not limiting, because a range of con-
ditions can be associated with ‘1’ and all other conditions
with ‘0’, or vice-versa. So, indeed, any categorical auxiliary
variable, with its values distributed in this manner, can be
used to elaborate the decision primarily based on HbA1c, the
main variable. Having this understanding, the rules involving
categorical auxiliary variables are presented in Table 2.
Table 2. Enhanced HbA1c rules for T2DM diagnostic using
nominal extension variables
 
 
HbA1c indecision 
interval 
Auxiliary variable Balanced 
Accuracy 
(%) From(%) To(%) Name Values 
6.00 6.64 Feet Reflex absent, reduced 84.64 
5.60 6.22 Ewing Result definite 84.06 
6.10 6.60 HT-Status yes 83.47 
5.80 6.22 CVD-Status yes 83.11 
 
The rule-sets, or simply rules, schematised in Figures 3 and
4 and parameterised in Tables 1 and 2 should be treated with
caution as there are various reasons why interval boundaries
may differ from the stated. Of course, firstly, one should
allow for variance in results due to choice of selectors and
their intervals to guide the data completion. Secondly, the
extension clause in a rule applies to a small and sparse subset
of data, so any point in or out can bring about a notable
change. Thirdly, towards the ‘Yes’ end, essentially due to
the overall rarity of T2DM in general population, there are
fewer data points to statistically rely on. Above all, interval
boundaries for HbA1c and the variables extending the rule
cannot precisely be determined because the data sample is fi-
nite. Particularly, the accuracy calculation involves counting
successes in prediction of possible outcomes. These counts,
and so the accuracy, change step-wise.
Extended HbA1c rules may or may not offer an improved ac-
curacy of classification, generally. Either way, any change in
accuracy should be measured relatively to the HbA1c indeci-
sion interval, which is rule dependent, for proper comparison.
Otherwise, any increase may appear to be very modest. A
surrogate criterion that can be watched instead when select-
ing a rule is presented by the indecision range itself, as any
increase in accuracy can be expected to be commensurate
with the data it accounts for. Particularly, the middle section
may disappear altogether if a rule that is being optimised
is not going to be more accurate than the HbA1c-only rule.
The QRS (which is an ECG waveform) linked rule at the
end of Table 1 is given as an example of this kind, where the
HbA1c indecision interval is exclusively narrow, and the rule
otherwise is not much different from the HbA1c-only rule
setting the benchmark for comparison, which appears on the
last line.
Rules depicted in Figures 3 and 4 are fairly simple, it is suffi-
cient to use the ‘over’ or ‘under’ construct to fully express
any such rule. More complex rules would include a number
of intervals subdividing the HbA1c range with possibly dif-
ferent descendent clauses attached to each interval, with each
clause defined by a single variable but is not limited to a sin-
gle threshold. The structures generated by the decision tree
algorithm used to initiate the search inspire, though, simple
rules consisting of a single interval exception on HbA1c with
a single threshold on the extension variable. The orientation
of boundary is often clear from the initial rule produced by
the decision tree. However, for many rules in Tables 1 and 3
explained next the orientation is also supported by data-wide
considerations as evident from Table 6, that is, how levels
of biomarkers and other indicators are generally different
between the control and diagnostic classes.
Table 3. T2DM diagnostic rules based on a single predictor
 
 
Decision Variable  Accuracy (%) 
Name Cutoff Unit Orientation  Class 0 Class 1 Balanced 
HbA1c 
(optimal) 
6.20 per-cent over 89.58 75.34 82.46 
HbA1c 
(standard) 
6.50 per-cent over 93.75 63.68 78.71 
8-OHdG 939 pg/mL over 99.84 43.50 71.67 
LDL 2.70 mmol/L under 72.44 68.16 70.30 
WCHR 0.582 pro-rata over 62.98 71.30 67.14 
Unisex 
Waist 
101 cm over 80.93 52.02 66.47 
AIP -0.0192 
nonlinear 
pro-rata 
over 60.74 71.75 66.24 
TC 5.14 mmol/L under 53.04 78.48 65.76 
BMI-1 48.3 kg/m over 63.14 63.23 63.18 
Feet 
Reflex 
Score 
0 point over 65.06 60.09 62.58 
BMI-2 30.1 kg/m2 over 73.88 51.12 62.50 
 
4. DISCUSSION
4.1 Contending risks
The rules in Tables 1 and 2 exploit the circumstance that
HbA1c is the strongest predictor of T2DM comparing to
other features in the tables. In fact, only FPG and PG in gen-
eral are rivals of HbA1c, and this is unsurprising because all
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three feature the glucose content in blood. Table 3 gives an
idea of what is achievable when rules based on a single pre-
dictor are optimised for accuracy using variables that follow
HbA1c on the IG list and also compares the optimal HbA1
rule to the standard one. However, the listing by diminishing
balanced accuracy in Table 3 gives a close approximation of
this order.
In the literature diagnostic rules with 90+% accuracy are
described as ‘exceptional’, those with 80+% as ‘great’ and
those with 70+% as ‘acceptable’[39] (although the platitudes
designating the ranges may be arbitrary). Thus, having op-
timised the HbA1c rule lifts it out of the obscurity of mere
acceptability, which is remarkable. The rule is great but is
not exceptional - this corresponds to the role given to HbA1c
in diagnosing T2DM, which is an additional check to verify
results of FPG and TPG probing:[8] “An HbA1c of 6.5% is
recommended as the cut point for diagnosing diabetes. A
value of less than 6.5% does not exclude diabetes diagnosed
using glucose tests.” Even though we find a better cut point
for HbA1c, FPG is more sensitive. Only few other rules,
using balanced accuracy for this analysis, are acceptable by
the above standard but fall well behind the optimal, or even
the standard HbA1c rule. We argue later in the text that
LDL and TC cannot be used in usual sense as predictors
of T2DM. The 8-OHdG rule is acceptable, but notice the
imbalance between the sensitivity and specificity, which are
individual accuracies for Classes 1 and 0, respectively. The
rule is particularly useless in predicting Class 1 and tells of
nature of 8-OHdG which elevation results from the action
of reactive oxygen species initiating a chain of free radical
conversions which are very unpredictable and impact many
established pathways.[19, 20] However the consistency of the
8-OHdG rule may have also been eroded by use of antiox-
idants. The WCHR, Unisex Waist, and atherogenic index
of plasma (AIP) rules are less than acceptable but can be
used as a reference point to some extent. Again, the Unisex
Waist rule is not balanced, but acceptable in respect of Class
0. We define Unisex Waist as WC for females and WC less
by 9.7 cm for males based on the means; however, a different
correction is applied in the standard oversize formula (WC
of 94 cm or more in men and 80 cm or more in women
places them into the increased T2DM risk category),[12] but
the standard is known to vary with jurisdiction, so there may
be locality specifics. At the same time, a study of a large,
diverse population of T2DM patients in the US reports only
7.7 cm difference in average WC for men and women,[23]
which suggests some other consideration involvement in the
mentioned standard. The WCHR and AIP rules are only
slightly imbalanced and then in favour of Class 1 where they
reach over the acceptability mark. In fact, the results look
alike. Perhaps, this is due to the nature of triglycerides (TG)
used in calculation of AIP defined as Log10(TG/HDL). The
BMI-1, Feet Reflex Score and BMI-2 rules are far from being
acceptable, yet the first two are balanced, and the last one
is acceptable in respect of Class 0. Here, BMI-2 is BMI in
the usual sense, that is, the weight to squared height ratio,
whereas BMI-1 is simply the weight (kg) to height (m) ratio.
It is important to recognise that accuracy of the single feature
and threshold predictors in Table 3, particularly accuracy
of the HbA1c rule can be potentially higher with respect to
diagnosis of actual T2DM as opposed to that estimated using
PG features. Till recently IFG and IGT were the primary
criteria required to determine the T2DM status.
4.2 Intermittent hyperglycaemia
The cutoff for HbA1c indicating transition to T2DM, as
found, is somewhat lower than the current recommended
level, but this may be due to cohort characteristics. However,
the World Health Organization (WHO) made concessions
having analysed a substantial body of evidence to date as fol-
lows.[8] “Levels of HbA1c just below 6.5% may indicate the
presence of intermediate hyperglycaemia. The precise lower
cutoff point for this has yet to be defined, although the ADA
has suggested 5.7% - 6.4% as the high risk range. While
recognizing the continuum of risk that may be captured by
the HbA1c assay, the International Expert Committee rec-
ommended that persons with a HbA1c level between 6.0%
and 6.5% were at particularly high risk and might be con-
sidered for diabetes prevention interventions.” The optimal,
or ‘precise’ point of T2DM onset at HbA1c 6.2% that we
find for heterogeneous population is clearly within the in-
tervals adopted by both ADA and WHO. Importantly, in
combination with inflammatory, oxidative stress and clinical
presentation markers a lower HbA1c cutoff associated with
T2DM has its own right to apply, which we also report and
that may to some extent explain the varied results obtained
world-wide for HbA1c as a clinical marker for T2DM.
4.3 Diabetic peripheral neuropathy
To require that Feet Reflex Score was more than zero, as in
Table 3, is the same as to verbally condition on Feet Reflex
being absent or reduced, as in Table 2. This score and the
equivalent expression of reflex weakness is derived from
five tests for reflex presence in feet, which extends also to
ankles and knees.[32] One of the five results is a summary
of the Semmes-Weinstein monofilament examination, which
is by itself a sensitive gage of feet neuropathy, even though
more involved.[40] In any test the reflex is found to be either
absent, reduced or present, which scores 1, 0.5 or 0, respec-
tively. To obtain the score the points are added up. Unlike the
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score, the reflex weakness is evaluated by taking maximum
of the individual test scores and expressing the result in a
word accordingly. The tests are intended for detection of
Diabetic Peripheral Neuropathy (DPN) in patients, which is
a well-known complication of T2DM attributed to chronic
hyperglycaemia. DPN is defined as presence of peripheral
nerve dysfunction in diabetics after exclusion of other causes.
A relationship between glycaemic variability and DPN has
been observed in T2DM patients even with well-controlled
HbA1c.[41, 42] DPN is a serious condition which can cause
ulceration of feet that, if cannot be treated, might require
amputation of affected lower limb extremities.[40] Testing for
DPN is theoretically meaningful as the high BP is generally
considered a co-factor of T2DM. It creates a favourable envi-
ronment for glucose to attach to cell receptors. And it is well
known that BP in feet is much higher than at the heart level.
4.4 Dyslipidaemia
Dyslipidaemia, characterised particularly by high TG, a com-
ponent of AIP, accompanies T2DM, but is there a strong
connection and how this is related to obesity? It is well
known that T2DM increases risk of CVD; however, can the
opposite be also true? One study reviews the connection
between HbA1c and lipid profiles.[43] The authors entertain
the view of strong connection and mention a report where it
was concluded that health education addressing behavioural
measures to reduce cardiovascular risk coupled with regu-
lar reviews of progress was able to improve HbA1c without
any specific, additional medical attention. An educational
program of this sort would recommend lifestyle changes
with emphasis on dieting and physically activity.[44] A tar-
geted study of the impact of lifestyle changes involving a
number of clinical sites across the US, where one half of
participants were required to fulfil dieting and modest physi-
cal activity recommendations, and another half was simply
educated about the benefits of diet and exercise, has shown
a dramatic improvement of participant condition in the in-
tensive lifestyle intervention group after 12 months of the
program.[23] Particularly, notable changes were observed in
body weight and HbA1c. All participants were T2DM pa-
tients independently medicated as prescribed by their physi-
cians. Engagement in physical activity is generally known
to improve prospects of T2DM patients.[45] However, low
carbohydrate diet (LCD) is now considered a mainstream
approach to tackle T2DM, although the treatment may be
very enduring. For example, a trial demonstrated a signifi-
cant reduction in HbA1c, TG as well as body weight in the
LCD cohort comparing to the control one, both IGT at the
baseline, and a significant increase in HDL after 12 months
of LCD, with LDL levels also decreased.[46] The weight loss
can be even more profound in the wake of very low calorie
dieting (VLCD) where fats are restricted more than carbohy-
drates comparing to LCD.[47] Although the last study does
not provide any of the aforementioned characteristics but the
body weight, it finds that levels of hormone leptin in VLCD
subjects were significantly less than in LCD ones, all obese
at the baseline, after 9 months of therapy, which is important
for this discussion. Adhering to VLCD for a sufficiently long
time makes possible just by itself achieving a full recovery
from T2DM.[48]
Theoretically the connection between dyslipidaemia and hy-
perglycaemia is plausible. In obesity adipose tissue reaches
limits of storing more TG, or fats. Particularly, the tissue
emits leptin - a hormone which hypothalamus should inter-
pret as a message of satiety. “Leptin is a hormone made and
secreted by adipocytes that acts on the brain to regulate food
intake and body weight. It can also act directly and indirectly
on peripheral tissues, as almost all tissues express the lep-
tin receptor,” according to one interpretation.[49] However,
with T2DM the starving cells must be sending a conflicting
message or the reception is only partial. For the same reason,
adipocyte ability to take and convert glucose to TG is also
limited. With or without T2DM, the issue of the hormone
leptin does not seem feasible if biochemically the limit is
not reached. Some drug designs actually exploit this circum-
stance and deal with T2DM if not by enabling the tissue
to store more fat then by using up the existing capacity so
long this is possible.[24] Under the T2DM conditions TG ab-
sorbed from food do not land in adipose tissue and circulate
in blood concealed in soluble chylomicron particles. Some
of it is eventually stored in liver and muscles which are not
specialised for this. The ectopic deposition of fats is a known
feature of T2DM. However, liver has a function of converting
fats to glucose which it stores and dispenses as necessary.
And it has another function, which is to convert TG to choles-
terol. However, this does not immediately happen; instead,
TG are packed into very low density lipoprotein particles
(VLDL) and dispatched into the blood stream. VLDL is
transformed to LDL largely made of cholesterol as neces-
sary. This shows the causal connection between TG and TC,
but one has to be sure when examining assay results how
the two are accounted for. On the other hand, the glucose
metabolism in T2DM is largely replaced by TG oxidation
for energy, creating a lower pH environment characteristic
of the disease. Incidentally, issue of leptin becomes resolved
when it sets off metabolism of fats in cells. Leptin enables
energy release from fatty acids (FA) in TG via activation
of AMPK, a kinase converting adenosine monophosphate
(AMP) back to triphosphate (ATP) when cellular energy lev-
els, particularly in muscles, are low[49] as follows. “Upon
activation, AMPK signals through its downstream substrates
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to restore normal energy levels by stimulating processes that
generate ATP (such as FA oxidation) and inhibiting those
that use ATP (such as TG and protein synthesis).” The activa-
tion of AMPK by leptin can either be direct, as explained, or
indirect, via signalling from the central nervous system.[49]
While TG is in demand, the acidic environment is harmful
and unsustainable without harsh consequences. So, the con-
centration of TG does not build up, but it is elevated if the
disease is progressing slowly. Although, it is known that
uncontrolled T2DM may result in a dramatic weight loss
within a very short time. This metamorphosis also supports
the premise that in obesity the storing capacity of adipose
tissue is reached. It is not clear what triggers this release
of TG; however, it is credible that lower pH substantially
changes the cellular biochemistry. Therefore, at least at early
stages or when controlled, obesity, usually gaged with BMI-
2, and T2DM are highly correlated. Storage of the life fuel in
adipocytes is the mechanism by which T2DM in possibility
is delayed. In obesity the limit is reached and the covert
T2DM becomes overt.
4.5 Waist-to-height ratio
WCHR appears to have much higher a standing though on
the list in Table 3 than BMI-2 and therefore is preferable.
The fact that WC is an important indicator of T2DM and a
better one than BMI is supported by a large body of evidence.
A dedicated to WCHR meta-analysis of results contained in
a large number of articles was conducted not long ago.[29]
It was concluded that WCHR (WHtR) is often better than
WC and both are consistently better than BMI for a range
of conditions, including T2DM (diabetes), CVD and HT.
WCHR is unit of measure independent and one can gather
that it is gender indiscriminate. The study, though, reports
results separately for men and women, and there possibly
exists a difference with respect to CVD. The gender differ-
ences otherwise are only slight, and the authors also find that
WCHR is ethnicity and possibly age invariant. While this
meta-analysis[29] selected only articles where the receiver
operating characteristic (ROC) approach was used, another
recent meta-analysis[28] focused on articles where cutoff val-
ues were proposed for WCHR and BMI as predictors of
several cardiometabolic outcomes to measure relative per-
formance of the metrics. Once again, in the large sample of
studies the majority was in favour of WCHR. Our choice of
WCHR over BMI as a selector variable in the algorithm for
data completion is though explained by the IG advantage of
the first. However, the WCHR attribute is much less supplied
with values than the BMI measures where weight instead of
WC is used. So, we linearly regress WCHR on BMI-1 and
use the formula to populate MV in the WCHR attribute. This
modified attribute is used as a selector; however, it is not
the actual WCHR. The filled values in the selector attribute
impact only how the actual one is clustered, which of course
has a lesser footprint than the clustering itself.
The proposed WCHR thresholds corresponding to BMI-2
ones are given in Table 4.
Table 4. Equivalent obesity thresholds for BMI-2 and
WCHR
 
 
BMI (kg/m2) Threshold Meaning WCHR (pro-rata) 
20 Underweight / Normal 0.450 
25 Normal / Overweight 0.525 
30 Overweight / Obese 0.600 
 
The thresholds were obtained by linearly regressing WCHR
on BMI-2 and rounding up the results as in the table. The
regression line is only slightly nonlinear, albeit the nonlinear-
ity can be expected theoretically. The threshold for transition
from normal to overweight state is particularly closely match-
ing values found for various cardiometabolic conditions in
the first meta-analysis:[29] “Importantly, WHtR offers advan-
tages of a simple boundary value which could be used for
men and women, and maybe children, of all ethnic groups ...
Analysis of suggested cutoff values from 34 analyses in 16
different papers showed that the mean of proposed boundary
values for WHtR, weighted for study size, in men and women,
respectively, was 0.52 and 0.53 for diabetes, 0.53 and 0.50
for CVD, 0.50 and 0.50 for HT outcomes ... The mean pro-
posed boundary value (the first cutoff level indicating risk)
for WHtR was 0.5.” Note that ROC analysis does not involve
calculation of cutoffs in order to compare discriminative
powers of different predictors, which is how the issue is ap-
proached in studies surveyed in the second meta-analysis.[28]
So, perhaps the thresholds estimated in first one[29] are indeed
on the safe side of respective conditions occurring, and are
not optimal. The optimal T2DM onset WCHR level in Table
3 is higher than the normal-to-overweight state change mark
in Table 4 but is within the range reported in the second meta-
analysis.[28] Particularly, the median value of 0.56 across
12 studies for “diabetes mellitus” in non-Asian populations
is less than, but is comparable to the one in Table 3, and
is virtually the same as for early stages of T2DM featured
in the clause complementing corresponding HbA1c rule in
Table 1. However, meta-analysis of 15 studies performed for
Asian populations[28] found a distinctly lower median value
of 0.51 for the assumed T2DM cutoff, which gives WCHR
if not ethnical then racial dimension.
4.6 HbA1c-only rule variation
The optimal HbA1c-only rule offers a much improved accu-
racy over the standard one, difficult to eclipse with a modified
rule (see Tables 1, 2 and 3). This makes it an easy choice
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if not for decision making, then for analysis. It is easier
to further discuss the rule optimality if the dependence is
visualised. Figure 5 presents results of balanced accuracy
evaluation for different cutoff values of HbA1c as a predictor
of T2DM. Unlike in all previous evaluation where the entire
dataset is treated as a single sample of the conceptual data,
we use ‘5x2’ sampling technique to plot the mean accuracy
and the standard deviation lines. This technique implies that
the data is randomly but proportionally to class member-
ships is distributed into two equally sized folds, as much as
possible, and the rule accuracy is evaluated separately on
the resulting samples. The whole procedure is repeated five
times. This is a known approach to bias reduction of the
perceived result variance attributed to data indiscriminately
sampled from an infinitely large, unrestricted pool.[50] The
accuracy is probed for each 0.1 fraction of HbA1c 1% be-
tween 5.0% and 7.0%. Notice inflection points between 5.9%
and 6.0% and between 6.5% and 6.6%. It is peculiar that
near these points there are ‘bottlenecks’ of increased rule
confidence relating a notably reduced standard deviation of
the sampled accuracy. This may be a result of a biased inter-
pretation of the existing knowledge about etiology of T2DM.
Particularly, the inflection point or a lower maximum past
6.5% is possibly a result of applying the standard HbA1c
rule. We will have an additional clue about the other inflec-
tion point. The higher maximum at 6.2% as found separately
using all data appears to be obscured by the ‘veil’ of least
confidence. This is particularly interesting as this possibly
explains the existing discordant opinion about a better cutoff
to diagnose T2DM by HbA1c than the current 6.5% and also
that additional factors are likely involved.
The presentation given in Figures 5, 6 and 7 that follow is
not equivalent but is similar to a ROC chart. Perhaps it is
even more revealing: although the sensitivity and specificity
are not independently plotted, it is possible to observe the
parameter that controls them. The parameter is HbA1c and
the balanced accuracy represents a synergistic effect of sensi-
tivity and specificity. Because either that sensitivity is high or
specificity is low, or other way around, the effective range for
balanced accuracy is between 50% and 100%, not between 0
and 100% as for any of the components.
4.7 Common complications
It is important to understand implications for decision mak-
ing if the impact of CVD and HT on population is varied,
particularly how steady is the optimal threshold. Figure 6
presents results of balanced accuracy evaluation for different
cutoff values of HbA1c as a predictor of T2DM, depend-
ing on whether CVD and HT are both present or separately
absent. The same technique of ‘5x2’ validation is used, al-
though only mean accuracies are shown.
Figure 5. T2DM prediction accuracy and standard
deviations for different HbA1c cutoff values
Figure 6. T2DM prediction accuracy for different HbA1c
cutoff values in presence or absence of CVD and HT
The profile does not fundamentally change if CVD records
are withdrawn. The “CVD absent” line practically overlays
the “HT and CVD line” also shown in Figure 5; so much
that precisely computed maxima for all of the data of the
two profiles given in Table 5 are collocated. This can be
expected as CVD is much less consequential for T2DM than
HT using the IG criterion. Note, however, that the T2DM
status and HbA1c are different variables even though highly
correlated. The treatment by statins may have left only a ves-
tige of CVD presence in affected subjects after the condition
was initially identified. However, if HT-only content of the
data is withdrawn - the “HT absent” line - the profile is much
different, particularly the maximum in Table 5 is at a notably
lower HbA1c level than for other lines. Surely, HT Status is
a stronger predictor than CVD Status; however, incidence of
HT in the population is also much higher than that of CVD,
so the balance of the data might have been grossly affected.
Together, this explains ‘sagging’ and unevenness of the “HT
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absent” profile. The vast and deep drop in accuracy visible
in Figure 6 and evident from Table 5 tells of important role
of HT presence in determining T2DM outcomes, and is con-
sistent with the theoretical base and experimental findings.
Taking into account, though, the uncertainty due to levelling
out of the curve about where the maximum might be, and
the unlikeness of HT being absent in populations affected
by T2DM, no correction of the threshold against the optimal
HbA1c-only rule for heterogeneous population is required.
Table 5. T2DM by HbA1c diagnostic optimal cutoff
variation in populations differently affected by CVD and HT
 
 
Population 
HbA1c 
cutoff (%) 
Balanced 
Accuracy (%) 
CVD and HT both present 6.20 82.46 
CVD absent, HT present 6.20 83.05 
CVD present, HT absent 5.90 79.98 
 
HT is a known circumstance abetting development of T2DM,
so much that the precursor of the two: namely, HT in addi-
tion to hyperglycaemia and/or dyslipidaemia is recognised as
metabolic syndrome (MS) – a distinct condition.[17, 43] How-
ever, HT is strongly associated with obesity[51] and obesity
with T2DM.[28, 29, 43] In this regard, the little deflection of the
“HT and CVD” line where the “HT absent” line joins it in
Figure 6 - the inflection point in Figure 5 past 5.9% seems
to be more on the part of the actual phenomenon than due to
the limited knowledge of the data given by a single set. Cer-
tain prejudice may have existed in diagnosing T2DM in HT
patients. This is the same, although a less persistent predica-
ment as the one existing in respect of the standard HbA1c
rule indiscriminately applied. Despite the substantial sagging
of the accuracy profile when HT content is removed from the
data, the additional influence HT Status exerts in determining
T2DM outcomes is very modest comparing to other variables
linked to HbA1c, as seen from Tables 1 and 2. Notice that
HT Status interferes with HbA1c in the area where HbA1c
is strong by itself, and also that the sagging seen in Figure 6
occurs in accordance with bounds set out in the modified rule.
This makes sense if HT merely accelerates HbA1c increase
in a prediabetic situation and is not directly involved with
the onset of T2DM. However, the sagging is sooner on the
part of large amount of data removed; particularly, it engulfs
the indecision region. CVD Status in Table 2 has little to
add to the HbA1c rule, although indeed it stretches the rule
wide. HbA1c levels were found to be useful indicators of
lipid levels[43] and as such may be good for identification of
T2DM patients with increased risk of CVD. However, our
results show that LDL and TC levels are reduced in T2DM
patients instead of being elevated, and we argue later in the
text that this is a result of medicinal intervention targeting
LDL. The fact that CVD Status props HbA1c below the opti-
mal cut point is an indirect evidence to this transformation.
That is, we should assume that T2DM patients with CVD
had initially high LDL and TC but then were treated for both
CVD and T2DM and this lead to moderation of HbA1c.
4.8 T2DM disease cluster
T2DM is long being diagnosed by FPG and TPG. Just by
itself this reveals the complex nature of the disease made of
closely related conditions:[52] FPG in excess of IFG captures
the moment of onset of insulin resistance; TPG in excess
of IGT captures the moment of onset of insulin deficiency.
The logic requires that IGT was preceding IFG, although
this connection is not simple. Therefore, a higher FPG has a
connotation of long existing T2DM and in this regard HbA1c
is probably more balanced a measure. The standard HbA1c
cutoff is well aligned with the IFG range.
A short screening program run in Hong Kong (HK) with the
purpose of evaluating applicability for subjects of Chinese
ethnicity of the recommended by ADA HbA1c criterion for
T2DM diagnostic[53] gives a unique opportunity to compare
results as the authors have tabulated sensitivity and speci-
ficity along with presenting the results in the ROC chart form.
A comparison of their results with ours is given in Figure 7.
Figure 7. T2DM prediction accuracy for different HbA1c
cutoff values in current evaluation and independently
reported
The similarity of the two balanced accuracy against HbA1c
profiles comes to the fore, as if ours was a magnified copy of
theirs, albeit with some qualification. An important aspect
of this for us is that the ‘trademark’ features of the accuracy
profile, enumerated in the graph, are not a result of fluctu-
ation due to data availability but are typical of the T2DM
phenomenon and diagnostic practices. The mission of the
study from HK primary healthcare was to prove that HbA1c
is not very suitable for T2DM diagnostic among subjects of
Chinese ethnicity, based on the observation that IGT is more
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prevalent than IFG in this population. This has a bearing on
the results which are probably biased. The biased representa-
tion is created by the selection of population for screening,
even though the numbers are larger than ours. These were
IFG persons, some diagnosed with T2DM in the process of
screening. Were other glycaemic categories also included -
this could have given more support to HbA1c values being
analysed for their affinity to T2DM. The caution that eth-
nical differences can influence HbA1c levels is expressed
now and then; however, the veritable truth about the change
imparted onto the involved haemoglobin is that it mainly
occurs through a non-enzymatic process.[1]
Despite accuracy in the HK study could be better, it is pos-
sible to discern that IGT is probably the best tool to warn
about impending T2DM in subjects of Chinese ethnicity -
the “golden standard”. Indeed, the trademark ‘dimple’ in the
accuracy profile (point 3) is just before the maximum (point
2) on the HbA1c ruler, and the other ‘dimple’ associated
with IFG (point 1) is much ahead of the maximum. The cor-
responding IGT and IFG ‘dimples’ in the profile evaluated
by us for the Australian rural population are at much lower
HbA1c values, both closer to the maximum. This looks as
if the entire IGT - IFG range was shifted to better frame the
maximum comparing to the other profile. Strangely enough,
the maxima of the two profiles are very close – between 6.2%
and 6.3%, at least visually, and considering the precision are
collocated. We found the best cutoff point at 6.2% and the
other study at 6.3%. Note that the curve tracing our result in
Figure 7 is the same as the corresponding one in Figures 5
and 6. Recall though that the 6.2% cutoff was found for all
of the data – twice larger a sample than used in validation,
although invariable. On the graph the point of maximum
may appear further up, but note that the summit is elongated
and the drawing is approximate. The 6.3% cutoff for the
other profile is also evaluated using all their data. However,
the chosen point of maximum is just the best one among
probed with the step of 0.1% and, considering the contin-
uum, can be less than 6.3%. The measure used to decide the
best cutoff point in the study compared with, is equivalent
to the balanced accuracy used by us. Even though ethnical
and racial specifics may impact sensitivity of the diagnostic,
T2DM is a complex phenomenon where insulin resistance
and insulin deficiency interplay, despite subpopulations may
exist displaying clear signs of one or the other. At the same
time, IGT appears to be universally more important than IFG
for early detection of T2DM, as further explained.
We previously suspected the ‘dimple’ at higher values of
HbA1c (point 1) to be a result of biased application of the
standard rule with the cutoff at 6.5%. This may be still true;
however, the other study result is not influenced by using
HbA1c as a diagnostic tool - it was itself evaluated. Both
the HbA1c standard and the upper bound of the IFG range
are indicators of impending hyperglycaemia and are presum-
ably well aligned with each other. Therefore, we assume
that this point is indeed associated with both aforementioned
instruments and is situated at higher HbA1c values than the
maximum at point 2. Both rules could have been strictly
followed. We also suspected the other ‘dimple’ at lower
values of HbA1c (point 3) to be a result of biased association
with presence of HT. Now we say it is IGT related. Again,
both may be true. The poor glucose clearance in a long run
can cause a sustained increase of BP, which we touch on
elsewhere in the text. Despite IGT is defined in terms of
higher PG levels than in IFG, the postprandial PG increase is
transient, and so IGT has to map to lower values of HbA1c
than IFG. Rules solely relied on invite a biased perception.
HbA1c between 5.6% and 6.3% is the uncertainty range
for T2DM diagnostic determined by the study conducted in
HK,[53] subject to the imposed limitations. The upper bound
of this range is essentially the point of maximum of balanced
accuracy, as explained. The lower bound, however, is defined
basically as a point of 95% sensitivity. This is at odds with
how the upper bound is set. At the same time, as seen from
Figure 7, the balanced accuracy approaches the 50% mark
asymptotically as HbA1c values get less. There is no specific
point of minimum to set the lower bound of the range by.
Although, there is a point preceding 5.6% where the rate of
accuracy growth with HbA1c increases dramatically (point
4). There is probably nothing special about this point, but
it is interesting that the growth onwards is steep and linear.
This potentially can be used to heuristically define the lower
bound of the uncertainty range for HbA1c as a predictor of
T2DM. However, to be consistent with the criterion used
for the upper bound, the principle of negligible error can be
used with balanced accuracy instead of sensitivity. Due to
the different range of possible values for balanced accuracy
as opposed to sensitivity this translates to the critical level
of 52.5% by the same standard as in the other study (point
5). The HbA1c values where the accuracy is just over 52.5%
should then be assigned to the uncertainty range. From Fig-
ure 7 the corresponding HbA1c level is approximately 5.3%
for our result and 5.4% for the result from the other study.
From the angle of this comparison the ethnical argument
undermining universality of HbA1c as a tool for T2DM diag-
nostic does not seem sustainable. All what was required is to
shift the entire uncertainty range by 0.1% which is relatively
a small correction. It also comes to light that if the standard
cutoff is redefined, HbA1c can become an instrument supe-
rior to both IGT and IFG, when paired with IGT, because the
uncertainty range by HbA1c probably includes all of the IGT
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range mapped to HbA1c, and a smaller cutoff value suits
better the agenda of early T2DM detection. The proposed
region that can be described as the impaired HbA1c range is
between 5.3% and 6.2%. However, anti-T2DM medication
could have caused a drift of HbA1c values – the concern
also voiced by authors of the study compared with.[53] The
pre-diabetic HbA1c range as defined by ADA is between
5.7% (over 5.6) and 6.4% (under 6.5).[2]
4.9 Diagnostic, monitoring and treatment
One review analyses pros and cons of using HbA1c for diag-
nosis of T2DM.[6] The authors note that in ADA guidelines
“A1C is indicated as a diagnostic tool alternative but not supe-
rior to blood glucose”. That is, health care professionals can
choose diagnostic tools best suited to situations they have to
deal with. Perhaps the main idea circulated in the article is
that there is a difference between diagnostic and monitoring.
Particularly the test for IGT is superior for diagnostic than
the tests for IFG or impaired HbA1c, which are better for
monitoring. The authors give a study example where it was
found that the standard HbA1c rule missed more than 60% of
cases of early T2DM identified by IGT.[54] This may explain
the jutted out portion of the classification accuracy vs HbA1c
profile in Figure 5 in the vicinity of the proper maximum.
That is, the standard HbA1c rule or the one based on IFG
was often solely relied on to determine the T2DM status.
However, the profile twist may have another explanation.
The DiScRi dataset has been accumulated over many years,
more than a decade. Although T2DM, CVD and HT are
slowly progressing, the screened subjects obviously took cer-
tain steps to reverse their ill conditions. A continuous use of
certain medicines may keep levels of some biomarkers down.
The initial rules generated by the decision tree algorithm are
sometimes ambiguous. A biomarker level as in a healthy
individual seems to be inconsistent with the person being
diagnosed with T2DM. This certainly applies to PG levels
that often can be suppressed by insulin injection. One has
to choose a particular branch of the initial decision tree and
verify its viability through optimisation. Particularly, the
8-OHdG rule is initially equivocal, prompting that causes of
this biomarker being high in subjects affected by the disease
might have been remedied to some extent. Ultimately, this
applies to HbA1c itself. It is possible that the optimality of
the threshold is to some extent affected by the data distribu-
tion portraying a treated or, sooner, experienced population,
conscious of health risks they are exposed to, and taking
necessary steps to prevent them. This may be not in the best
interests of working out rules for diagnostic of a disease,
in general, yet the impartiality requires that the population
was taken as is. On the other hand, at the time that many
T2DM medicines strive to achieve HbA1c reduction,[24] the
statins addressing causes of CVD may somewhat increase
HbA1c,[55] so the overall effect is not obvious.
To help further discussion of rules in Tables 1 and 3, means
and standard deviations of the involved variables are stated
in Table 6 for the two classes of the data. The statistics were
extracted from the original, incomplete DiScRi data. The
Student’s two-tailed, unpaired t-Test was used in order to
compare feature means for different cohorts of population.
This is a standard statistical procedure; however, the strong
assumption of normality of data distribution is made in re-
spect of each variable. The result of the t-Test is p-value,
the smaller the more distinct are the compared means. To be
affirmative about the comparison a significance threshold by
p-value is selected. It is usually set to .05. Table 6 shows the
t-Test result, in particular.
Table 6. Original data statistics for T2DM diagnostic rule
features
 
 
Feature 
Control Class Diagnostic Class  t-Test 
p-value Mean St. Dev. Mean St. Dev. 
HbA1c 5.78 0.44 7.09 1.13 .000 
LDL 3.15 0.80 2.41 0.94 .000 
TC 5.20 0.89 4.50 1.05 .000 
WCHR 0.564 0.078 0.621 0.089 .000 
AIP -0.071 0.278 0.102 0.273 .000 
Unisex Waist 90.8 12.2 99.8 15.1 .000 
BMI-1 46.6 8.5 51.1 9.6 .000 
BMI-2 27.7 5.1 30.4 5.7 .000 
Foot Reflex Score 0.433 0.746 0.901 1.067 .000 
TG 1.36 0.74 1.74 0.84 .000 
HDL (mmol/L) 1.43 0.37 1.27 0.36 .000 
8-OHdG 256 232 1,190 1,230 .000 
IL-6 28.2 22.6 47.2 32.8 .000 
LDL / HDL 2.29 0.82 1.97 0.80 .000 
Creatinine 74.1 18.6 79.9 22.4 .008 
IHR Approx. 
Entropy 
1.18 0.21 1.13 0.24 .023 
GSH / GSSG 6.46 4.37 5.35 3.26 .057 
Protein 70.8 4.4 71.4 4.7 .331 
CRP 2.88 2.57 3.20 4.03 .480 
IHR Sample 
Entropy 
1.38 0.32 1.35 0.30 .555 
QRS (over 10 s) 102 17 103 16 .854 
 
4.10 Oxidative stress
The results for 8-OHdG and glutathione (GSH) are particu-
larly interesting. The first is a biomarker of oxidative stress
due to causes of T2DM and the second is an antioxidant
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which function is to offset this stress. Oxidation of the re-
duced GSH gives rise to a modified species, glutathione
disulphide (GSSG). GSSG is supposed to be converted back
to GSH by the enzyme glutathione reductase. However, the
oxidative stress is also implicated in inhibition of this en-
zyme.[56] Thus, GSH levels are expected to drop in T2DM
patients and the deficit of glutathione reductase exacerbates
this. The accumulation of GSSG makes GSH-to-GSSG ra-
tio even more sensitive a measure of oxidative stress than
GSH itself. This is supported by results of previous obser-
vations.[56] Indeed, the GSH-to-GSSG ratio levels are lower
in the diagnostic class comparing to the control one, as seen
from Table 6, although the distinction between levels is just
over the significance threshold of .05 by p-value of the t-Test.
The conditions under which DiScRi data is collected cannot
be described as pure whereby only untreated subjects are
selected. Providing that, one could probably demonstrate
a higher accuracy of T2DM prediction by antagonising the
data classes from the start. However, the performance at the
82% accuracy mark of the optimal HbA1c-only rule is by
no means poor and is much improved in combination with
8-OHdG, which is responsible for 5% accuracy hike, as seen
from Table 1. The product of the two is fortunate because
the 8-OHdG-only rule is grossly insensitive, as discussed,
but much of this is offset by the sensitive HbA1c-only rule.
However, much less known of 8-OHdG than of HbA1c, with
missing rates as different as eight and three in ten, respec-
tively. So, the rules in Tables 1 and 3 involving 8-OHdG can
be offered only tentatively. Despite the actual numbers are
not that small, there might be inconsistencies with respect
to fair sampling. We outright dismissed variables with more
than 90% of unknown values. Because the class mix is likely
to be grossly underrepresented, these variables may appear
to be very promising indicators of presence/absence of the
disease; however, this cannot be verified. Nonetheless, the
power of 8-OHdG as a predictor of T2DM is supported by
previous reports.[22] At least one third of the full content for
any other variable in the text is known.
4.11 Inflammation
C-reactive protein (CRP) and interleukin-6 (IL-6) are known
to be indicators of inflammation processes associated with
T2DM[17] and are routinely collected for diagnostic of the
disease. In brief, the inflammation is caused by expansion of
adipose tissue with vasculature development falling behind,
which is also known to increase BP. The undersupply of nu-
trients and constriction of capillaries is causing, particularly,
hypoxia in some adipocytes that signal this condition, which
in turn is intended to stimulate proliferation of the capillary
network. This involves secretion of IL-6. Other response to
the inflammation is lipolysis and FA release by adipocytes
themselves. Under hypoglycaemic conditions the FA release
is intended to restore energy levels, explaining endocrine
down-regulation of insulin production by pancreatic β-cells.
However, this is not normal under hyperglycaemic condi-
tions, presenting the conundrum. Macrophages is another
source of signalling. Macrophages infiltrate adipose tissue
to collect debris from cells or whole cells that disintegrate
or become dysfunctional, which is partly self-induced in re-
sponse to inflammation. More macrophages are attracted
by the positive feedback which also involves secretion of
IL-6. Thus, elevated IL-6 is one of the signs of increasing
adiposity and therefore is a marker of obesity. IL-6 is not
only present in obesity but actually abets T2DM by indi-
rectly contributing to insulin resistance,[17] that is, before the
glycation of cellular receptors is effective. Issue of this pro-
inflammatory cytokine also stimulates hepatic production of
CRP - an acute-phase response agent to inflammation, part
of the innate immunity, which contributes to the autoimmune
suppression of insulin producing β-cells in pancreas,[17] and
this is not only abetting T2DM but in a long run makes it
less and less reversible. And without insulin the cellular
glucose uptake is limited. Therefore, both IL-6 and CRP
are considered acceptable early markers of T2DM. From the
original data statistics in Table 6 the IL-6 level in the T2DM
group is significantly higher comparing to the control, and
the optimal rule utilizing IL-6 in addition to HbA1c does
not contradict this. A study[21] which has contributed to the
DiScRi data, reports a significantly increased inflammation
in their prediabetes compared to their control group, repre-
sented by elevated levels of both IL-6 and CRP. From Table
6 the increase in the CRP level is not as convincing as in
the IL-6 one; however, the diagnostic group in the current
research is different - T2DM. The threshold of zero for CRP
in Table 1, that is, any inflammation is actually meaning-
less and it can be observed that the accuracy of the CRP
rule is the same, perhaps only marginally better than of the
HbA1c-only rule on the next line. Besides, it does not vary
mapping of the HbA1c decision regions. Therefore, CRP use
in the context of modified HbA1c rule is superfluous. The
artefact value of this rule is that despite a substantial span
of the indecision interval the modification does not improve
on accuracy of the underlying HbA1c-only rule. Depletion
of CRP levels may have been brought about by medications
protecting function of pancreatic β-cells. In fact, many anti-
T2DM drugs attenuate CRP levels, directly or indirectly.[17]
In this connection, while all rules in Table 1 offer mitigations
of the HbA1c-only rule, whether the standard or the optimal,
in view of the general discussion about their applicability,
we would be more interested in modified rules extending
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the HbA1c useful range, that is, helping early detection of
T2DM. This means smaller ‘from’ values of the indecision
interval in Table 1. Particularly, the IL-6 linked rule has this
property and also offers a higher accuracy. This confirms
utility of IL-6 as a pre-clinical marker of T2DM. There is
another consideration to heed when applying rules involving
whether IL-6 or CRP. While CRP has been acclaimed as
even a better marker for CVD than LDL, the assay is rec-
ommended to be repeated if any unrelated sepsis or injury
is present, as this can render a response much stronger than
is warranted by the CVD decision range.[18] This concern
should equally apply to IL-6, another inflammation marker,
even though in the context of T2DM.
4.12 Cardiac autonomic neuropathy
The Ewing Result, encountered in Table 2, is based on three
heart rate (HR) and two BP measurements obtained under
different conditions.[57] The Ewing system is used for diag-
nostic of Cardiac Autonomic Neuropathy (CAN) in patients,
which is a complication of DM. HR tests involve the lying-
to-standing, the deep breathing, and the exhalation against
a closed airway (the Valsalva manoeuvre) exercises. BP are
evaluated in the hand grip, and the lying-to-standing situa-
tions. Of each quantity it is decided whether it should be
considered normal, borderline or abnormal, and the results
are combined to assess presence of CAN. It is regarded ‘ab-
sent’ - if all tests are normal or one is borderline, ‘early’-
if one HR is abnormal or two are borderline, ‘definite’ - if
two or more HR are abnormal, ‘severe’ - if additionally to
‘definite’ one or two BP are abnormal or two are borderline;
or else the result is ‘atypical’.[36] It has been reported[58]
that HbA1c variability is positively associated with presence
of CAN, identified using the Ewing battery of tests. The
longitudinal aspect of the DiScRi data can be exploited to
some extent to evaluate variability of HbA1c in connection
to CAN. This was not attempted presently. CAN, regarded a
complication of DM, can actually precede hyperglycaemia
by many years.
Instantaneous (given a moment of time) HR (IHR) estimated
from ECG recordings can be used for diagnostic of vari-
ous health abnormalities in patients. Utility of Sample En-
tropy, a particular measure engaging IHR for identification
of CAN was previously demonstrated.[16] Sample Entropy
“was developed to reduce the bias caused by the self matching
in approximate entropy which is a mathematical approach
to quantifying the complexity and regularity of a system,”
as claimed.[16] So, we shall assume the two measures are
similar; however, only Sample Entropy is discussed in the
concerned paper[16] where an expression for it can be found.
Both IHR entropy measures are featured in Table 1. The rules
have ‘under’ orientation corresponding to the original data
statistics for these variables in Table 6, although a desired
clearance between the two classes is not guaranteed. In the
study behind the paper[16] data for a small number of T2DM
patients with and without CAN was analysed to evaluate var-
ious IHR measures. CAN was diagnosed using a single com-
ponent of the Ewing system out of the consideration of data
availability. The measure relied on was lying-to-standing
HR, admissibility of which as a sole indicator of CAN was
supported by previous independent analyses. Despite the
study is small, the authors conclude, with references to simi-
lar results elsewhere, that their “. . . observations demonstrate
that SampEn decreases in CAN+ patients relative to CAN- di-
abetic subjects.” They also engage the decision tree approach
to estimate a Sample Entropy threshold to determine CAN.
Our effort to have any missing entries filled, particularly in
all variables the Ewing system draws on, pays with the abil-
ity of relying on all data, and we find the threshold to be at
1.54 which is very close to 1.56 reported in the mentioned
study.[16] Of course, the rule in Table 1 is just an enhanced
HbA1c rule for T2DM diagnostic. It is only because of the
similarity between our and the other party results for IHR
Sample Entropy we can hypothesise that CAN is involved
and that at least some of CAN is explained by T2DM. The
utility of the IHR Sample Entropy is also acknowledged in
another study concerned with CAN diagnostic in a mixed
population of T2DM subjects and healthy controls.[15] The
analysis was performed on a sample of DiScRi data, and the
first study may as well have contributed to project. However,
there is a number of ways of calculating the quantity.[35] We
assume that the same standard to how it is done applied in
both studies.[15, 16] IHR Approximate Entropy is not notion-
ally different from IHR Sample Entropy, and so qualitatively
same result is expected. It appears though that IHR Sample
Entropy is much worse on its own in determining T2DM
outcomes, as seen from Table 6, which correlates with other
results obtained for CAN diagnostic in the DiScRi space.[35]
The rules involving these variables, or even more to the point
Ewing Result previously discussed, basically claim that if it
is not an overt T2DM then it is CAN, which positions CAN
within the T2DM network of realisations.
4.13 ECG waveforms
Various guidelines on DM prevention and treatment ad-
vise,[44] that “high blood sugar puts a strain on the heart,”
which is a general principle, and intuitively this may lead
to an elevated BP. Glucose is much bigger a molecule than
water, it is well soluble in the latter, and so increased con-
centration of the former should also elevate viscosity of the
blood plasma. Remarkably, the Ewing system for diagnostic
of CAN exploits the HR and BP criteria despite the very
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different nature of CAN. Yet from the biological perspective
higher PG levels can lead to free radical damage of ANS in
patients with inadequately controlled T2DM. Indeed, hyper-
glycaemia causes increased HR in observations.[15] Is this
effect, though, discernable in ECG unaided? The obvious
choice of feature to examine first is the QRS complex, a
waveform so denoted - the main impulse, distinct on a nor-
mal ECG. However, the original data statistics in Table 6
render such an optimism groundless, with the ten seconds
average QRS duration levels being no different in the T2DM
cohort comparing to the control. Some indirect evidence
supporting this also exists. Particularly, glycaemic control
has been shown to be a marker for ventricular tachycardia
and sudden cardiac death, independent of the QRS interval
obtained from electrocardiology investigations, especially in
high-risk people with DM.[59] Indeed, QRS has a very narrow
foothold in the modified HbA1c rule in Table 1. Shorter QRS
intervals can be expected due to HR increase and vice-versa.
This lines up with the ‘under’ orientation of the rule in Table
1. Neither this contradicts other available evidence suggest-
ing that a weakened heart will show longer than normal QRS
intervals. Particularly, it was reported that the cutoff for ab-
normal QRS intervals is 100 ms and prolongation of QRS
(120+ ms) occurs in 14% to 47% of heart failure patients.[60]
Despite this consistency, the modified HbA1c rule featuring
QRS in Table 1 offers no real advantage over, and indeed is
not much different from the HbA1c-only rule in the same
table.
4.14 Glycation and dehydration
Although protein (the total serum content of) as a parame-
ter is not closely watched in DM literature, its elevation is
generally indicative of some chronic condition leading to de-
hydration - both is true in respect of T2DM. The main part of
serum protein content - albumin is thought to be instrumental
in cellular fluid retention. This is partially explained by the
relatively small size of this protein, so that produced in large
quantities it helps to maintain the plasma osmotic pressure,
as reviewed.[61] The homeostasis otherwise requires that the
excessive glucose was flushed out, which is indeed what is
observed in DM and for what it gets its name - siphoning out
of the sweet. Hence, albumin is BP regulator in DM. What
is also peculiar about specifically albumin in serum is that
it serves as a transporter for free FA, probably due to their
insolubility otherwise. This is important for this discourse
as FA were identified as a factor of insulin deficiency.[17]
The advent of free FA in obesity and T2DM is due to in-
flammation, as discussed, and so albumin might be there
to meet the increased FA concentration, in the first place.
The second aspect of raised protein levels in T2DM patients
is how it is measured. Any protein in serum is exposed to
glycosylation under DM conditions, just like haemoglobin.
So, even at the same molar concentration in serum, protein
is gaining more weight per mol in DM subjects comparing
to unaffected ones.[1] Indeed, the protein concentration in
Table 1 is expressed as weight per volume and the rule is
appropriate. However, the trend to protein content eleva-
tion in serum at T2DM in Table 6 is not strongly expressed,
perhaps due to the additional variance brought about by indi-
vidual differences and the unspecified protein content being
measured. Note that HbA1c is expressed differently, as a
relative concentration which varies less. Also, when exam-
ining serum protein levels one should be concerned with
how the data was obtained. Different labs contributing to the
same database may use different methods, which of course
applies to any parameter being measured. However, it may
appear being purposeful to apply generic and therefore less
costly assay methods to capture non-specific protein con-
tent, which may be then ignorant of the effect of glycation.
Nevertheless, there exist assays that directly measure gly-
cated protein content:[1] “The fructosamine assay is the most
widely used alternative. It is a measure of glycated serum pro-
tein, which incorporates glycated albumin. Methods are also
available for the quantification of glycated albumin specifi-
cally.” Albumin is particularly attractive for its deemed high
potential as a marker for DM:[1, 61] it has a shorter half-life
(21 days) compared with haemoglobin, so it could be used
as a shorter-term glycaemic control; it is not easily altered
by an abnormal haemoglobin metabolism; the amount of
non-enzymatic glycation of albumin is nine times more than
in the case of HbA1c; glycation of albumin is ten times faster
than of haemoglobin.
4.15 Cholesterol profiles and lipid lowering drugs
Various guidelines on T2DM treatment target reduction of
LDL and TC.[12, 44] Here, no reduction is required because it
is already in place, Table 6, to which rules in Tables 1 and
3 do not contradict. Once again, this is likely a result of the
awareness. The rational is as follows: CVD complicates DM
(DM increases CVD risk[39]); CVD can be treated, and so the
negative impact of DM compensated by reducing LDL and
TC. A medical practitioner would include a lipid lowering
therapy into the treatment plan because CVD is life threat-
ening and DM is not. On the other hand, the lipid lowering
drugs (LLD) are known to be effective, especially at early
stages of CVD. LLD may be not optional when complement-
ing T2DM medications that increase CVD risk, particularly
those with a side effect of weight gain.[24] The authors of a
study mentioned in connection to 8-OHdG[22] use essentially
the same data as in the current research, although selectively,
to contrast their research purposes, and incidentally the data
is much better known, with “missing data rate” no more than
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20%, which we assume applies to 8-OHdG. Apart from con-
firming the 8-OHdG result they also note the impact of LLD:
“Medication use may have contributed to some of the results
noted in our study. However, there was no significant differ-
ence in the use of antihypertensive medication between the
two groups. Statin use was higher in the IFG group and may
have contributed to the borderline normal levels of LDL in
both the groups but despite their reported antioxidant effects,
the IFG group had significantly higher 8-OHdG. . . . 19.4%
of the control group used statins compared with 37.5% of
the IFG group.” Another study using a sample of the DiS-
cRi data actually acknowledges the TC level reduction:[62]
“Both total cholesterol and HDL-C were significantly lower
in the IFG group, while triglycerides and LDL-C showed
no difference between the groups.” It was also noted that
“. . . LDL-C does not play a major role in diabetes disease
progression.” In this study the use of statins was claimed
to be nearly twice as much, significantly more frequent in
the IFG than in the control group. Yet another study gets
qualitatively the same result as ours, although the LLD con-
nection is played down:[21] “Unexpectedly, the prediabetic
subjects were characterized by a slightly improved blood
lipid profile. A possible explanation for that phenomenon
is that even though the differences in statin use between the
two groups were only small, this could still have had an in-
fluence on the blood lipid outcomes of the prediabetes group,
since statins lower LDL and increase HDL levels”. Again, at
least some of the data acquired in that study is accessed in
the current research. This authenticates our result, although
not by independent reporting. However, general improve-
ment of DM care outcomes, particularly drop in HbA1c,
LDL and TC levels was concurrently and independently ob-
served in NSW, Australia.[63] The authors write: “Significant
improvements in HbA1c, total Cholesterol, HDL and LDL
(excluding Triglycerides) levels were also found between
2000 and 2004 which corresponded with implementation
of the Diabetes SIP” (i.e. Screening Incentive Payments).
However, the overall reduction trend pertaining to TC is ev-
ident there since the beginning of the data stream in 1995.
In this instance urban NSW population was studied. For the
reference, the DiScRi program is run in rural NSW since
2002. Australia-wide, having analysed the official statistics,
the diabetes-related death rate has declined by 20% from
1997 to 2010, which is traceable to improvements in lipid
levels, blood pressure and blood glucose levels.[64]
4.16 Cholesterol level factors
It is on the public record that through this time statins have
seen rise to the heights of best profit generators pharmaceu-
tical companies worldwide ever new. While LLD market-
ing by the companies should not be discounted, there are
stronger factors the significant reduction of LDL and TC in
populations can be linked to, apart from the LLD efficiency.
Perhaps one of them is rise of Asian markets and the effort
by Australian meat producers, embracing the philosophy
of free trade, to meet the demand, even at expense of af-
fordability for the domestic consumer. So, this channel of
external cholesterol supply could have been economically
constricted. Surprisingly, the role of meat consumption in
development of CVD and T2DM is inadequately covered in
the literature,[65] although the dwindling evidence that exists
suggests “. . . a possible negative impact of processed pork on
glucose-insulin metabolism and a possible positive impact of
pork intake on waist circumference and HDL-C.” We previ-
ously noted the success of LCD and VLCD treatments with
emphasis on dietary proteins.[46, 47] Meat is a major source of
proteins; however, it comes with cholesterol. As much as the
cholesterol in HDL is desirable, it is undesirable in LDL from
the perspective of CVD and T2DM treatment. Another socio-
economic factor of scale is general aging of the population,
seeing the pension age risen several times in the recent past.
According to one report[66] “. . . the Australian Age Pension
eligibility age for women has increased from 60 in 1995 at
the rate of six months every two years during the past decade,
reaching the constant eligibility age of 65 for males in 2014.
From 2017, the pension qualifying age for the two genders
will start rising again from 65 years old by six months every
two years until reaching 67 years of age in 2023.” This would
ensure that working elders stay physically active and person-
ally satisfied – the factors considered significantly reducing
risks of T2DM,[45] while age is a CVD risk factor.[39] Physi-
cally active T2DM patients, studied on one occasion,[45] had
a better health-related quality of life (HRQL) comparing to
inactive ones, but it was quickly degrading with progressing
obesity. HRQL in this study accounted not only for various
physical but also social, emotional and psychological abili-
ties. The correlation between physical and mental domains
of HRQL does not preclude the possibility of T2DM being
independently reversible through improvement of mental
wellbeing. The pension age hikes is an extraordinary devel-
opment because the age did not change in Australia since
1910[66] and is, of course, a result of general improvements
in economy and health care. It is also known that reduced
LDL and TC levels are characteristic of advanced age (70+
years),[43, 67] which may be due to the general slow-down
of enzymatic activity and endocrine decline, let alone the
unfavourable survival rate in this cohort. Unlike a one-time
evaluation effort,[43] the other study[67] is a longitudinal one,
which allowed the authors to conclude that the reduction is
not explained by non-survival, neither it is weight related and
otherwise lessens the probability of CVD events. All partici-
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pants on any medication modifying cholesterol levels were
excluded from the analysis. Explaining the mechanism the
authors concur with others that:[67] “The observed decline
in cholesterol levels might reflect inflammatory responses to
infections, which increase with age, or age-related reduced
cholesterol absorption from the intestine.”
However, the scenario implicating medication is very proba-
ble even though in the current research the medicinal aspect
of the DiScRi data is not being pursued: from Table 6 it is
evident that LDL, the main target of statin medication, is less
by 23% in the T2DM cohort comparing to the control - it
is far less than statins are known to achieve in trials.[68, 69]
The awareness may have also improved, not only the medi-
cation, and also the taken for granted access to information.
There are behavioural measures that are very effective and
the general population just is not educated enough to take
full advantage of few simple wisdoms.[44] In view of the
explained, the LDL and TC extended HbA1c rules in Table
1 should be seen as artefacts rather than valid rules for diag-
nostic of T2DM. However, to be impartial one should not
discard the existing evidence that older patients prescribed
statins can develop T2DM after long use, found by exam-
ining results of a many large trials,[55] although the risk is
small: “Meta-regression showed that risk of development of
diabetes with statins was highest in trials with older partic-
ipants, but neither baseline body-mass index nor change in
LDL-cholesterol concentrations accounted for residual vari-
ation in risk. Treatment of 255 (95% CI 150-852) patients
with statins for 4 years resulted in one extra case of diabetes.”
That is, comparing to the same number of participants on
placebo and in excess of the DM pro-rata number inherent
in the population to whom statins are recommended, which
extends to the placebo cohort.
4.17 Experimental setup
However, any misconception about perceived LDL and TC
levels in different categories of subjects should be avoided.
Firstly, in one-time studies the information how participants
are medicated is often unreported. For example, one study
finds a positive substantial correlation of HbA1c with TC
but a faltering one with LDL.[70] In another study the posi-
tive correlation is found for both TC and LDL; however, the
levels in low and high HbA1c categories are less than 5%
different for both TC and LDL.[43] Actually, in the last study
the low and high categories are set well apart, separated by
a medium HbA1c range (6.0% - 9.0%); and TC and LDL
levels dip before they surface, which may represent patients
successfully treated with LLD known to be especially effec-
tive at early stages of CVD. Both studies and another one[71]
are one-time, the volunteers are not patients undergoing a
treatment and how they are medicated is unknown, possibly
poorly.
Secondly, some efforts are small[70] and this is even acknowl-
edged.[71] In the last study a positive substantial correlation
was found for HbA1c with both TC and LDL. By compari-
son, the amount of data in another mentioned study,[43] where
only a small increase, if any, is detected in TC and LDL lev-
els with HbA1c, is more than ten times the amount of data in
either of the two.[70, 71]
Thirdly, studies are narrowly focused. For example, a number
of studies are interested in T2DM patients only.[43, 68–71] No
healthy cohort is included in any of the studies to compare
with. Perhaps this parsimony is not groundless. It is difficult
to assemble a healthy cohort because requirements might
be very specific. A T2DM-free cohort is not the healthy
one. Particularly, in the current research all subjects may
independently experience CVD and HT. Any comparison
involving marker levels in different categories of subjects
should be correctly aligned. Even within the same T2DM co-
hort understanding of what is low and high HbA1c level may
differ. For instance, these subcategories in one mentioned
study[71] (below or above 7.0%) do not match those in an-
other mentioned study.[43] Also, the population cohort being
studied may be loosely defined. For example, it is improper
to compare results for T2DM and T1DM populations or treat
them as if they were same. The etiology of T2DM is very dif-
ferent. Perhaps in respect of the lipoprotein profiles a T1DM
population should be included with the healthy cohort.
Also, it is worth nothing that LDL, HDL, TC and TG contents
together or individually can be assayed by different methods.
LDL is often only estimated using the other three quantities;
however, even the expression for it may differ.[43, 70] All four
quantities can be directly assayed.[71]
Unlike all above-mentioned, one study[72] compares diabetic
(T2DM) participants to non-diabetic counterparts, so it imple-
ments exactly the same sampling approach as in the current
research. The use of statins was accounted for, although it
was not a trial, and the authors report the following: “Rate
of hypertension, dyslipidaemia, and thereby systolic blood
pressure and statin use were significantly higher in the dia-
betic group, while the serum levels of cholesterol, HDL-C
and LDL-C were significantly higher in the control group.”
While the non-diabetic participants were almost not using
statins (4%), the T2DM patients were heavily relying on
them (42%). The LDL levels were down by 17%, TC levels
down by 14% and HDL levels down by 13% in the T2DM
cohort comparing to controls. All lipid related concentra-
tions were directly measured, which adds to the credibility
of the results. Although the study is small, it is noteworthy
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that we observe exactly the same trend, and the numbers are
close to what we get. From Table 6 the average LDL is less
by 23%, TC by 13% and HDL by 11% in the population
with T2DM compared to that without. We, of course, do
not know in this instance the exact numbers of statin users
in either category of individuals screened under provisions
of DiScRi, only suspect it was high in the T2DM cohort.
Similarly, there is a study in the DiScRi space where T2DM
subjects are compared to healthy controls, and where the
cholesterol profiles were examined, even though the study
is seemingly unrelated, concerned with CAN.[15] The use
of unspecified anti-cholesterol medicines was there higher
by T2DM patients (68%) than by healthy subjects (25%).
Accordingly, the cholesterol levels were down in the T2DM
cohort comparing to controls as follows: LDL by 23%, TC
by 14%, and HDL by 14%. This is indeed very close to what
we get.
4.18 Atherogenic index
A previously mentioned study[22] sought a connection be-
tween DNA damage in endothelium due to DM, of which 8-
OHdG is an indicator, and TG. It is well known, though, that
TG is up and HDL is down in T2DM patients, which is a part
of dyslipidaemia accompanying T2DM.[71] In this regard,
the connection between TG and WCHR should not be over-
sighted, which was earlier discussed. Therefore, AIP given
as Log10(TG/HDL) is a sensitive measure of T2DM.[73] The
atherogenicity of AIP is on the part of HDL - the lacking
“good cholesterol” to unsettle build-up of the “bad choles-
terol” due to LDL, but the excessive TG, which is a feature
of T2DM, also increases the propensity to CVD in T2DM
subjects, which explains the index utility for diagnostics of
both CVD and T2DM.[71, 73] There is no contradiction here
from the data point of view (see Table 6). However, the HDL
level may have been inadvertently impacted by the LLD use,
as proposed, although this conflicts with the statement in a
previously mentioned paper,[21] weakly supported by results,
that statins lower LDL but increase HDL. Other sources
claim that there are good drugs to lower LDL cholesterol, but
there are no drugs that can raise HDL cholesterol effectively.
Indeed, modus-operandi of the statin medication is to trick
the metabolism into destroying free LDL particles in serum
instead of recycling cholesterol in them.[74] Incidentally, this
explains why statins are especially effective at early stages
of CVD. Therefore, both LDL and TC are expected to fall.
However, the HDL level is not guaranteed to rise, if only
relatively to LDL - the cholesterol is shared by LDL and
HDL. Although, effectively, LLD covers for HDL. The pat-
tern observed by us and quantified above is no different. By
comparison, LDL and TC levels reported elsewhere[68] in
subjects intensively treated for T2DM, which included statins
for LLD with some exception but also antihypertensives and
anticoagulants, were down by about 2/5 and 1/5 from charted
results, respectively, comparing to their opposite numbers on
conventional therapy by other means, while HDL was not
reported. Another study was specifically looking at effects of
atorvastatin in T2DM subjects without a history of CVD.[69]
The full effect was evident in months rather than years, so the
trial had to be discontinued sooner than planned. Both the
placebo and the atorvastatin groups were otherwise similarly
medicated. The lipid marker levels at the end of the trial in
the atorvastatin group comparing to the placebo group were
down by about 2/5 and 1/5 for LDL and TC, respectively
(remarkably, the same as the above[68]), while HDL levels
were no different in the two groups, as charted. Hence, the
potential of LLD, statins in particular, is much higher than
the possible effect of treatment with LLD seen in our results,
which are therefore realistic.
4.19 Creatinine
A similar situation exists in respect of creatinine featured
in Table 1. An increase of creatinine content in blood is
characterising muscle work. This is unlikely to happen in
DM because of the undersupply of glucose to muscles. In-
deed, one study finds lower serum creatinine levels in T2DM
subjects.[75] However, this is not what the rule linked to crea-
tinine projects and, from Table 6, the levels are confidently
higher in the T2DM cohort than in the control one. Creatinine
in plasma is a waste product which level is routinely used for
estimation of Glomerular Filtration Rate (GFR), so that if
creatinine is raised this may be a sign of renal incapacity.[12]
This explains that antihypertensive medication may elevate
plasma creatinine levels. Indeed, in a study-contributor to
the DiScRi data[21] “. . . the percentage of subjects on antihy-
pertensives was remarkably higher in the prediabetes group
(35.8%) compared to the control group (5.2%) . . . ” Instead,
the contingent investigated in the first study[75] was that of
non-diabetic office workers who did not have T2DM at the
beginning of the trial, were not medicated, and some 10%
of whom had developed T2DM over the trial period which
lasted few years. It was hypothesised that a population ex-
posed to T2DM is characterised by atrophy of musculature -
that is, not only by accumulation of fat. However, the cellular
energetics can also play a part.
5. CONCLUSION
The test for HbA1c is easily administered and can be used for
estimation of long term blood glucose average level required
for identification of the T2DM. However, many HbA1c tri-
als were inconsistent suggesting that a single threshold to
determine T2DM may be too simple for the diverse popu-
lation. There exist markers that alone are not good, clear
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indicators of T2DM but were surmised to be useful when
paired with HbA1c, particularly near the internationally rec-
ommended threshold of 6.5%. The current research deploys
novel data analytics to discover co-markers and co-marker
related HbA1c thresholds that enhance the predictive abil-
ity inherent in HbA1c in identifying T2DM. Particularly, it
provides a novel insight into interactions of oxidative stress
markers, inflammatory cytokines and lipids with HbA1c in
T2DM classification.
Data mining, or data analytics, has been deployed with clini-
cal data for numerous purposes in recent decades including
enhancement of diagnoses, improvement of prognoses, early
identification of adverse drug reactions, and a variety of in-
surance and efficiency related objectives. However, one of
the main challenges for data mining in healthcare is dealing
with missing values, noise and outliers. To deal with many
unknowns it makes sense attracting any additional knowl-
edge from the domain of diagnostics when pre-processing
the data. Getting results in the decision tree form offers sim-
ple rules that enlighten interpretation of the phenomenon in
hand. Rules obtained from data with missing values may
lead to a discovery if they reveal rare indicators endowed
with a high potential. To our knowledge, data mining has
not been previously deployed to discover thresholds of a
main marker and revised thresholds when combined with a
co-marker, also identified via analytics.
The application of data mining in this way requires a dataset
where very many plausible markers are collected from the
same patients. The dataset used in the current research is
derived from a diabetes and cardiovascular screening unit
data collection run in recent years in Australia, currently
listing 2,700 participant attendance records on 300 attributes.
Sophisticated methods for imputing missing values were
deployed and decision tree induction was used in combi-
nation with optimisation to find precise HbA1c thresholds
for relevant co-markers. A new visual representation of the
thresholds and co-markers was developed in order to facili-
tate interpretation of proposed rules.
A number of rules were extracted this way from the data and
optimised for performance. This set includes the HbA1c-
only rule using a single cutoff level for diagnostic of T2DM,
and others that extend this rule by using a second variable.
This allows to mitigate the HbA1c based decision depending
on patient circumstances and expands the space for decision
making in proximity of the cutoff. It has been confirmed
that the optimal HbA1c cut point for diagnostic of T2DM
is lower than the currently recommended 6.5%, what earlier
studies imply, and was estimated to be at the level of 6.2%.
Moreover, the useful range of HbA1c can be extended using
additional variables identified in the literature as associates
of T2DM. This study presents for the first time objective
positive results of emerging blood biomarkers for classi-
fication of T2DM. 8-OHdG, GSH-to-GSSG ratio and the
pro-inflammatory cytokine IL-6 are oxidative stress markers
that have been previously implicated in the pathophysiology
of T2DM, especially in the prediabetes stage. This further
emphasises the utility of the adopted data mining approach.
However, HbA1c is individually much stronger than any of
the extension variables, so that many composite rules only
slightly lower the optimal threshold. Nonetheless, the rules
offer an improved accuracy of T2DM classification. Such are
HbA1c rules extended by BMI and WCHR. However, it was
found that individually WCHR, or the waist-circumference-
to-height ratio, is a much stronger predictor of T2DM than
the conventional BMI, adding to the existing evidence in
support of this effect. WCHR or BMI are attractive for their
simplicity but do not improve much on the optimal thresh-
old for HbA1c. At the same time, the related dyslipidaemia
parameter AIP propagates the HbA1c-only rule below the
optimal value.
The proposed rules cannot perform worse than the HbA1c-
only rule because of the applied optimisation, and it was
found that the optimal HbA1c-only rule is more than 80%
accurate. However, due to the small size of the region where
the modification is applied only a modest improvement of
the overall rule performance can be expected. Despite this,
the primary interest in diagnostics is posed by early identifi-
cation of the possible demise, and any increase in accuracy
of the diagnosis should be appreciated closer to the point in
the parametrical space, given by individual circumstances,
where the transition to the ill state is likely to occur. How-
ever, medication may much change the fabric of this space.
Particularly, the trend exhibited by lipoproteins changes to
opposite the usual perception of their levels being higher in
T2DM subjects comparing to healthy people. This may be
a feature of the data but is partially confirmed by indepen-
dent reports. A future study should involve the medicinal
component of the database.
The standard rule does not account for well-controlled T2DM
where HbA1c values are in the normal range. However these
records were retained in the dataset to reflect more closely
the population sample. In addition, the HbA1c cutoff level,
as defined by WHO guidelines, was originally set based on
the presence of diabetic retinopathy and is thus linked to a
complication of DM and not the occurrence of DM. However,
DM may also manifest in other conditions such as DPN or
CAN. That is, removing those with DM and HbA1c above
the task force 6.5% would still leave some DM contingent
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explained by other features. In this light, it seems to be more
appropriate to regard DM an unobservable variable influ-
encing others that are observable. It is not that DM can be
independently diagnosed and then any complications, rather
it is seen in complications. More narrowly, this all applies to
T2DM.
A limitation of the proposed rules is that HbA1c is combined
with one other variable, which can be seen as inconclusive.
A different variable teamed with HbA1c may inform the op-
posite. A generic approach to consolidation of all evidence
is presented by feature construction where the feature-set
is extended using binary features generated from the rules
and then the problem of conflict resolving is reduced to the
conventional classification one. A feature of the DiScRi data
that could have given a lesser edge to our results is that, once
a T2DM diagnosis was initially arrived at for a patient, it is
assumed to be correct regardless of the PG level that may go
up or down. Both these incongruences are mainly due to the
data scarcity. The role of additional biomarkers in prediction
or classification of T2DM mandates further exploration with
carefully selected population samples, ideally from a larger
database.
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